SEARCH · Search PubMed
Results for “Atrial Flutter”
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
False electrocardiographic diagnosis of atrial flutter.
Explore the source record for details and available documents.
[Use of disopyramide in the prevention of recurrence of atrial flutter and fibrillation].
Explore the source record for details and available documents.
Electrocardiogram of the month. Atrial flutter.
Explore the source record for details and available documents.
Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators.
BACKGROUND: Currently available antiarrhythmic drugs have limited efficacy for acute termination of atrial fibrillation and flutter, especially if the arrhythmia is not of recent onset. The purpose of this multicenter study was to determine the efficacy and safety of repeated doses of intravenous ibutilide, a class III antiarrhythmic drug, in terminating atrial fibrillation or flutter. METHODS AND RESULTS: Two hundred sixty-six patients with sustained atrial fibrillation (n = 133) or flutter (n = 133), with an arrhythmia duration of 3 hours to 45 days, were randomized to receive up to two 10-minute infusions, separated by 10 minutes, of ibutilide (1.0 and 0.5 mg or 1.0 and 1.0 mg) or placebo. The conversion rate was 47% after ibutilide and 2% after placebo (P < .0001). The two ibutilide dosing regimens did not differ in conversion efficacy (44% versus 49%). Efficacy was higher in atrial flutter than fibrillation (63% versus 31%, P < .0001). In atrial fibrillation but not flutter, conversion rates were higher in patients with a shorter arrhythmia duration or a normal left atrial size. Arrhythmia termination occurred a mean of 27 minutes after start of the infusion. Of 180 ibutilide-treated patients, 15 (8.3%) developed polymorphic ventricular tachycardia during or soon after the infusion. The arrhythmia required cardioversion in 3 patients (1.7%) and was nonsustained in 12 patients (6.7%). CONCLUSIONS: Intravenous ibutilide given in repeated doses is effective in rapidly terminating atrial fibrillation and flutter and under monitored conditions is an alternative to current cardioversion options.
Atrial flutter: contemporary electrophysiology and catheter ablation.
Explore the source record for details and available documents.
A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study.
The safety and efficacy of a 10- to 15-mg/h continuous infusion of intravenous diltiazem were evaluated in 47 patients with atrial fibrillation or flutter who first responded to 20 mg or 20 mg followed by one or more 25-mg bolus doses of open label intravenous diltiazem. Of the 47 patients, 44 responded to the bolus injection and were randomized under double-blind conditions to receive either a continuous infusion of intravenous diltiazem (10 to 15 mg/h) (23 patients) or placebo (21 patients) for up to 24 h. Seventeen (74%) of the 23 patients receiving diltiazem infusion and none of the 21 with placebo infusion maintained a therapeutic response for 24 h (p less than 0.001). Over 24 h, patients receiving diltiazem infusion lost response significantly more slowly than did those receiving placebo infusion (p less than 0.001). Nonresponders to the double-blind infusion were given an additional bolus injection of open label intravenous diltiazem and administered an open label 24-h intravenous diltiazem infusion. The overall proportion of patients maintaining a response to a 24-h infusion of intravenous diltiazem under double-blind or open label conditions combined was 83% (34 of 41). Efficacy of the 24-h infusion of intravenous diltiazem was similar in elderly versus young patients, those who did versus those who did not receive digoxin and those weighing less than 84 versus greater than or equal to 84 kg. However, intravenous diltiazem appeared to be more effective in atrial fibrillation than in atrial flutter. No significant untoward effects were noted.(ABSTRACT TRUNCATED AT 250 WORDS)
Antiarrhythmic actions of clemizole as pharmacologic evidence for a circus movement mechanism in atrial flutter.
Explore the source record for details and available documents.
[Treatment of paroxysmal forms of auricular fibrillation and atrial flutter in a cardiological hospital].
The results of treatment of paroxysmal forms of atrial fibrillation and flutter are analysed in a group of 503 patients with attacks lasting up to 3 weeks. The sinus rhythm was restored in 84.7% of patients, in only 3% of cases was electro-impulse therapy resorted to. In alcohol toxic form of atrial fibrillation and flutter potassium chloride was the most effective drug for restoration of the sinus rhythm in 47.1% of cases, and if used with cardiac glucosides in 64.7%. In atrial fibrillation and flutter of other etiology the method of choice was a combination of quinidine with isoptine either by itself, or after saturation of the body with potassium chloride (85% cases of sinus rhythm restoration).
What's your reading? Atrial flutter.
Explore the source record for details and available documents.
Right atrial angiographic evaluation of the posterior isthmus: relevance for ablation of typical atrial flutter.
BACKGROUND: Gaining anatomic information about the posterior isthmus is not generally part of flutter ablation procedures. We postulated that right atrial (RA) angiography could rationalize the ablation approach by revealing the conformation of the isthmus. METHODS AND RESULTS: In 100 consecutive patients, biplane RA angiography was performed before ablation to guide catheter contact with the isthmus along its length. Angiography showed a wide variation in the width of the isthmus (17 to 54 mm; 31.3+/-7.9), its angle with the inferior vena cava in the right anterior oblique projection (68 degrees to 114 degrees; 90.3+/-9.0 degrees ), and its lateral position relative to the inferior vena cava in the left anterior oblique projection. A deep sub-Eustachian recess was revealed in 47%, with a mean depth of 4.3+/-2.1 mm (1.5 to 9.4). A Eustachian valve was visualized in 24%. Ablation resulted in bidirectional conduction block (which could be transient) in all, with a median of 2 dragging radiofrequency (RF) applications (2.3+/-2.5 RF applications; 57 degrees C, < or =99 seconds each). Permanent block was achieved in 99%, with a median of 3 RF applications (3.4+/-3.0). The presence of a Eustachian valve or concave isthmus was associated with statistically more RF applications; the same trend was seen for patients with deep pouches. The number of RF applications decreased statistically throughout the study, indicating a learning curve. No patient had a recurrence after a follow-up of 13+/-11 months. CONCLUSIONS: Right atrial angiography reveals a highly variable isthmus anatomy, often showing particular configurations that can make ablation more laborious. Rational adaptation of the ablation approach to these anatomic findings may contribute to successful ablation.
Acute pulmonary edema after overdrive for atrial flutter.
Explore the source record for details and available documents.
An unusual artifactual cause of apparent atrial flutter.
Explore the source record for details and available documents.
PULMONARY ATRESIA WITH DILATED RIGHT VENTRICLE. A CASE WITH CONGENITAL ATRIAL FLUTTER.
Explore the source record for details and available documents.
Effects of atrial extrastimulation and rapid pacing on atrial flutter cycle.
Explore the source record for details and available documents.
Endocardial catheter fulguration for treatment of atrial flutter.
Explore the source record for details and available documents.
Increase in frequency of conduction over accessory atrio-ventricular pathways upon transition from atrial fibrillation to atrial flutter.
Explore the source record for details and available documents.